Panacea Biotec Limited announced the appointment of Narotam Kumar Juneja as Additional Director on the company’s Board, with effect from April 1, 2022.
According to the company’s exchange filing, “we would like to inform you that the Board of Directors of the Company has, on the recommendation of Nomination and Remuneration Committee, appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022.”
Narotam Kumar Juneja has done Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations. He has rich experience of over 40 years in pharmaceutical operations (including in the Company) and has executed multiple internationally approved projects worth $150M+ for reputed companies.
He has earlier been associated with the Company as Vice President Operations & Projects during 2003-2006 and again as Chief Operating Officer during 2010-2014. He has also worked at senior positions with Dawa Group Ltd., Kenya and several other companies in India including Unichem Laboratories, Ranbaxy Laboratories, Systopic India and Dabur India.
Panacea Biotec is a global generic and specialty pharmaceutical and vaccine maker registered in India with principal offices in New Delhi, Mumbai, and Lalru.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.